The recombinant human market is a sub-sector in the biotechnology industry dealing in the generation and marketing of recombinant human proteins which are formulated from recombinant DNA technology. These proteins are incorporated in a numerous number therapeutic approaches, for chronic diseases, inherited diseases, and diseases such as diabetes, haemophilia, and cancers. The market comprises a very broad array of products such as hormones, monoclonal antibodies, blood factors, enzymes etc. which are now being developed and employed more often because of various advantages in terms of efficacy and safety as well as producibility as opposed to traditional methods of production. This market is growing due to the developments in biomanufacturing technique, increased funding on biotech research, and elevated incidence of diseases involving protein therapy.

The global market for recombinant vaccines is one of the most vibrant segments in the overall global vaccine market owing to the continuous progress of biotechnology along with the growing importance of immunization stake. Recombinant vaccines are developed with the use of recombinant DNA technology through which genes coding for particular antigens are incorporated into host cells in order to generate massive production of requisite immune reactions.